Overview Insulin Glargine Versus Twice-Daily NPH Status: Completed Trial end date: 2009-08-01 Target enrollment: Participant gender: Summary To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone. Phase: Phase 4 Details Lead Sponsor: Charles Drew University of Medicine and ScienceCollaborator: National Center for Research Resources (NCRR)Treatments: InsulinInsulin GlargineInsulin, Globin Zinc